BioNTech SE
@BioNTech_Group
Tomorrow at #SABCS25, Dr. Schmid will share the study design of the global phase 3 ROSETTA Breast-01 trial evaluating a PD-L1 x VEGF-A bispecific antibody plus chemotherapy in PD-L1 negative TNBC.
Join the poster session at 12:30pm CST in Exhibit Hall.
Join the poster session at 12:30pm CST in Exhibit Hall.
0 20